Immuneel CEO: CAR-T Therapy Needs Insurance Umbrella

HEALTHCAREBIOTECH

Overview

Immuneel Therapeutics has partnered with Impact Guru and CarePal Money to improve access to its CAR-T cell therapy, a personalized cancer treatment. CEO Amit Mookim is pushing for insurance companies and regulators to include these high-value therapies under insurance products, aiming to overcome the significant upfront cost barrier and extend patient benefits.

Immuneel Therapeutics Pushes for CAR-T Therapy Access

Immuneel Therapeutics is working to expand patient access to its CAR-T cell therapy, a cutting-edge treatment for certain blood cancers, through new partnerships. The company has teamed up with healthcare crowdfunding platform Impact Guru and lending firm CarePal Money. CEO Amit Mookim is actively engaging with insurers and regulators to bring these high-value therapies under the insurance umbrella.

Addressing High Treatment Costs

The CAR-T cell therapy involves modifying a patient's own T-cells to target and destroy cancer cells. This single-infusion therapy comes with a significant upfront cost of approximately ₹35 lakh. Despite the high price, it offers a potentially life-altering outcome without the need for lifelong treatments. Immuneel Therapeutics aims to treat about 100 patients with adult B-cell Non-Hodgkin Lymphoma by March 2026.

Financing and Crowdfunding Avenues

This initiative follows a year of commercialization for Immuneel, which has reported encouraging patient response data from its network of 60 hospitals. Impact Guru will leverage its digital crowdfunding platform and a donor network of over 50 lakh contributors to help patients raise funds. Simultaneously, CarePal Money will facilitate structured credit by connecting eligible patients with its NBFC partners, offering tailored loan and financing options for medical treatment. This dual pathway aims to provide flexibility and financial security.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.